The Cholangiocarcinoma Foundation Annual Conference brings together researchers, clinicians, patients, policy makers, and others invested in the field of cholangiocarcinoma.
Poster Roundup: Boosting Checkpoint Inhibitors, Resistant Mechanisms in Cholangiocarcinoma
Research presented at the 2021 Cholangiocarcinoma Foundation Annual Meeting focused on precision medicine and therapeutic targets.
Overcoming Challenges in Clinical Trials for a Rare Cancer
At the 2021 Cholangiocarcinoma Foundation Annual Conference, experts discussed clinical trials in cholangiocarcinoma and the ways in which clinical trials overall can be made more available to patients.
Dr Michael D'Angelica: The Importance of Genomic Testing in Hepatobiliary Cancer
Michael I. D'Angelica, MD, FACS, of Memorial Sloan Kettering Cancer Center, gives insight on genomic testing and its growing role in cholangiocarcinoma.
Dr Funda Meric-Bernstam Highlights Aspects of Successful Clinical Trials
Funda Meric-Bernstam, MD, chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, discusses some of the key aspects of successful trials.
In Cholangiocarcinoma, New Targets, New Therapies, and Some Old Ones, Too
Last year, pemigatinib, the first targeted therapy in cholangiocarcinoma was approved for previously treated patients with FGFR2 fusions or rearrangements.
Management of Biliary Obstruction in Patients With Cholangiocarcinoma
At the 2021 Cholangiocarcinoma Foundation Annual Conference, experts discussed guidelines and real-world data for the management of urgent symptoms in patients with cholangiocarcinoma who have biliary stents or drains.
Dr Funda Meric-Bernstam on Immunotherapy in Cholangiocarcinoma
Funda Meric-Bernstam, MD, co-chair of the 2021 Cholangiocarcinoma Foundation Annual Conference, gives her insight on immunotherapies in cholangiocarcinoma.
Dr Michael D'Angelica on the Necessity of Multidisciplinary Collaboration in Hepatobiliary Cancer
Michael I. D'Angelica, MD, FACS, of Memorial Sloan Kettering Cancer Center, discusses multidisciplinary care and why it is so important in hepatobiliary cancers.
Patient-Driven Platform Offers Real-World Insights Into Cholangiocarcinoma
On the first day of the Cholangiocarcinoma Foundation Annual Meeting, Elli Brimble, MS, MSc, Ciitizen’s head of Clinical Operations, offered insights from an ongoing study based on data provided by patients.
Recent Advances and New Methodologies in Cholangiocarcinoma
Discussions at the start of the 2021 Annual Cholangiocarcinoma Foundation Conference centered on challenges and advances made during the COVID-19 pandemic, and the potential of liver transplantation in cholangiocarcinoma.
Dr Funda Meric-Bernstam on Why the Patient Voice Is So Important
Funda Meric-Bernstam, MD, co-chair of the 2021 Cholangiocarcinoma Foundation Annual Conference, gives her input on the importance of hearing from patients and advocates as well as physicians in discussions around cholangiocarcinoma treatment.
Dr Al B. Benson on the Importance of Multidisciplinary Care in Hepatobiliary Cancers
Al B. Benson, MD, FACP, FASCO, professor of medicine and director for Cooperative Groups at the Robert H. Lurie Comprehensive Cancer Center, stresses the importance of approaching difficult hepatobiliary cancer settings with a multifaceted care team.
2 Clarke Drive Cranbury, NJ 08512